Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PTAFR | P25105 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10900650 | 0.88 | GMNN (0.78) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL10899022 | 0.88 | GMNN (0.78) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL10900707 | 0.88 | GMNN (0.78) | GMNNUSP2LMNAPTAFRMTOR | |
| Bromide SCHEMBL8701422 | 0.83 | GMNN (0.71) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL8538731 | 0.83 | GMNN (0.70) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL10506196 | 0.82 | GMNN (0.69) | GMNNUSP2LMNAPTAFRMTOR | |
| Hydrochloric Acid SCHEMBL9575824 | 0.81 | GMNN (0.68) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL10899413 | 0.79 | GMNN (0.67) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL10898664 | 0.79 | GMNN (0.67) | GMNNUSP2LMNAPTAFRMTOR | |
| SCHEMBL10900342 | 0.79 | GMNN (0.67) | GMNNUSP2LMNAPTAFRMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126987-A1 | METHODS FOR TREATING CYTOKINE STORM SYNDROME AND RELATED DISEASES | GENEROS BIOPHARMA LTD. (KY) | 2023-04-27 | — | — | US | claimed |
| EP-4125894-A1 | METHODS FOR TREATING CYTOKINE STORM SYNDROME AND RELATED DISEASES | Generos Biopharma Ltd. (KY) | 2023-02-08 | — | — | EP | claimed |
| CN-115484953-A | Methods of treating cytokine storm syndrome and related diseases | 健艾仕生物医药有限公司 | 2022-12-16 | — | — | CN | claimed |
| WO-2026090492-A1 | TUMOR-ACTIVATED CELL ENGAGERS AND METHODS OF USE THEREOF | Xilio Development, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | XILIO DEV INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116940-A1 | MASKED CYTOKINE POLYPEPTIDES | XILIO DEV INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250275951-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2025-09-04 | — | — | US | disclosed |
| CN-113286812-B | Masked cytokine polypeptides | 西里欧发展公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4554965-A1 | ENGINEERED CLEAVABLE FC DOMAIN AS CARRIERS AND METHODS OF USE THEREOF | Xilio Development, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12280120-B2 | Tumor-specific cleavable linkers | Xilio Development, Inc. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250101075-A1 | MASKED IL-2 CYTOKINES AND METHODS OF USE THEREOF | Xilio Development, Inc. | 2025-03-27 | — | — | US | disclosed |
| US-20230028959-A1 | MASKED CYTOKINE POLYPEPTIDES | Xilio Development, Inc. | 2023-01-26 | — | — | US | disclosed |
| CN-115484953-A | Methods of treating cytokine storm syndrome and related diseases | 健艾仕生物医药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220306716-A1 | MASKED CYTOKINE POLYPEPTIDES | Xilio Development, Inc. (US) | 2022-09-29 | — | — | US | disclosed |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022115865-A2 | TUMOR-SPECIFIC CLEAVABLE LINKERS | Xilio Development, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022051721-A1 | COMBINATION COMPOSITIONS AND METHODS FOR TREATING CANCER | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| EP-0836852-A1 | Use of amlexanox for the manufacture of a medicament for treating aphtous ulcers | CHEMEX/BLOCK DRUG, JV (US) | 1998-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116940-A1 | MASKED CYTOKINE POLYPEPTIDES | TNFRSF9, IL36G, TNFSF11 | GMNN 2032/4885USP2 886/4885LMNA 1674/4885 |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | GMNN 4216/4885USP2 4302/4885LMNA 1822/4885 |
| US-20230126987-A1 | METHODS FOR TREATING CYTOKINE STORM SYNDROME AND RELATED DISEASES | IL6, IL2, IL15 | GMNN 4809/4885USP2 3416/4885LMNA 3194/4885 |
| US-20260115302-A1 | TUMOR-SPECIFIC CLEAVABLE LINKERS | SPPL2B, SPPL2A, CTSL | GMNN 4684/4885USP2 321/4885LMNA 1399/4885 |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTC, OAT, MYOC | GMNN 2613/4885USP2 2539/4885LMNA 2409/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GMNN 4177/4885USP2 4107/4885LMNA 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.